Close menu




September 30th, 2022 | 10:59 CEST

Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

  • Biotechnology
  • Pharma
  • Investments
  • Technology
Photo credits: unsplash.com

About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: BIOGEN INC. DL -_0005 | US09062X1037 , XPHYTO THERAPEUTICS | CA98421R1055 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Biogen - Breakthrough in Alzheimer's Disease

    This week's news gives hope to 30 million people worldwide: the US company Biogen has achieved a breakthrough in the fight against Alzheimer's disease. Together with its Japanese partner Eisai, the Company has published study results that underscore the efficacy of the drug Lecanemab. In the otherwise incurable neurodegenerative disease, nerve cells in the brain gradually die. Typical Alzheimer's symptoms include memory problems, disorientation and confusion. In the course of the disease, personality and behavior change. Many sufferers become restless, aggressive or depressed. In addition, speech and judgment decline.

    The two groups said that data from a study involving 1795 participants show that the progression of the disease is significantly slowed. After all the COVID vaccine news in recent months, investors worldwide celebrated this medical breakthrough. The Biogen share was trading as much as 40% higher in pre-market trading. It had to be briefly halted from trading at the start on Wall Street. Eisei rose 17%.

    "Today's announcement provides hope to patients and their families that Lecanemab, if approved, may slow the progression of Alzheimer's disease and have a clinically meaningful impact on cognition and function," said Michel Vounatsos, Chief Executive Officer at Biogen. "Importantly, the study shows that removal of aggregated amyloid beta in the brain is associated with a slowing of disease progression in patients with early-stage disease." Plans call for approval in the US later this year and in Europe in 2023.

    XPhyto Therapeutics - Using psychedelics to fight depression

    Another neurological disorder is depression. Worldwide, 350 million people are affected by this disorder of the brain. Depressed people suffer from anxiety, overthinking, strong self-doubt, hopelessness and lack of motivation. According to the German Society for Psychiatry, Psychotherapy and Neurology (DGPPN), there is a 16 to 20% chance that everyone will develop a severe depression requiring treatment at least once during their lifetime.

    Psychiatrists often prescribe antidepressants to their patients as a supportive treatment for psychotherapy. But the risk of dependence on the substances remains even after discontinuation. Depending on the length of time taken, the body and psyche become accustomed to the substitutes. According to the journal "Depression heute" meta-analyses, even after the obligatory two weeks after discontinuing the drug, the risk of dependence can persist for up to a year. Prof. Voderholzer, medical director of Schönklinik Roseneck, says "What amazes me most as a scientist and clinician personally is that, to my knowledge, despite a 60-year history with antidepressants, a variety of different substances, and an immense number of studies over short periods of time, there is not a single major randomized controlled trial that has attempted to investigate possible discontinuation and rebound effects in a clinical population over a longer period of time."

    What many do not know: Psychedelics like LSD, mescaline, and hallucinogenic mushrooms do not cause addiction. And that is where XPhyto Therapeutics comes in, in the development of drugs to treat depression.

    The Canadian Company specializes in the development of psychedelic pharmaceutical drugs for the treatment of mental illnesses such as depression, anxiety, addiction and trauma-related stress disorders. XPhyto Therapeutics is developing processes for the industrial production of pharmaceutical-grade psychedelic compounds, including psilocybin and mescaline. The potential for treating depression is immense, and a collaboration with the Technical University of Munich (TUM) has been set up for this project in particular.

    **In addition, XPhyto Therapeutics' pipeline includes Point-of-Care Diagnostics and biosensor products for early detection of other diseases.

    BioNTech - Defeating testicular cancer with mRNA technology

    Bundesliga fans likely already know: within a few months, the fourth case of a player diagnosed with testicular cancer has been reported. Testicular cancer is a malignant disease that occurs in the testicles. As it progresses, it can also affect the epididymis and vas deferens. Testicular cancer is a less common tumor disease, accounting for 1.6% of all cancers. According to the Robert Koch Institute (RKI), 4,070 men develop this malignant testicular tumor each year.

    Testicular tumors mainly affect young men between the ages of 25 and 45. It is the most common new cancer in men at this age, accounting for 20-30% of all cancer cases. The average age of men diagnosed with testicular cancer is 38 years.

    BioNTech now presents further promising data from the ongoing Phase 1/2 clinical trial of its novel CAR-T cell therapy approach, BNT211. The product, also based on mRNA technology, is specifically designed for use in advanced tumors.

    "The new data support the encouraging results we had previously observed for BNT211. Together with the recently granted PRIME status for BNT211 for the treatment of testicular cancer, we feel encouraged in our strategy to combine two of our technology platforms in one therapeutic approach, especially for difficult-to-treat tumor indications," explained Prof. Dr Özlem Türeci, Chief Medical Officer and co-founder of BioNTech. BNT211, a drug for the treatment of testicular cancer, was recently approved by the European Medicines Agency (EMA) as a third- or late-stage therapy for patients with advanced cancer.


    Investors should give innovative pharmaceutical and biotech companies their own space in their portfolios. Medical breakthroughs such as slowing Alzheimer's disease through Biogen's new drug or non-addictive psychedelics as a therapy for depression through XPhyto Therapeutics have arrived in the here and now. In addition to legally mandated and detailed research cycles, a mature market access strategy is needed to ensure that breakthrough drugs and therapeutics find their way into outpatient and inpatient care. Every investor experienced just how far-reaching such measures can go during the Corona pandemic. BioNTech appears to have scored the next coup with its therapeutic agent in the fight against testicular cancer.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read